【摘要】 目的 探讨血清胃泌素释放肽前体(ProGRP)和神经元特异性烯醇化酶(NSE)在晚期非小细胞肺癌中的表达及其临床意义。方法 收集晚期非小细胞肺癌患者75例，采用电化学发光免疫分析法检测血清中PorGRP和NSE的表达。结果 不同年龄、性别、吸烟史、美国东部肿瘤协作组(ECOG)评分及分化程度的晚期非小细胞肺癌患者血清ProGRP和NSE水平相比差异均无统计学意义(P>0.05);血清ProGRP和NSE水平与晚期非小细胞肺癌患者T、N分期无显著相关性(P>0.05),随着患者临床M分期中转移部位数目的增多，血清ProGRP和NSE水平显著升高(P<0.05);晚期非小细胞肺癌腺癌患者血清ProGRP和NSE水平显著高于鳞癌患者；EGFR基因阳性(突变型)患者血清ProGRP和NSE水平显著高于EGFR基因阴性(野生型)患者(P<0.05)。结论 血清ProGRP和NSE表达与晚期非小细胞肺癌患者病理类型、EGFR基因型及临床TNM分期中转移数目有关，这对于指导临床治疗及病情评估具有较高的检测意义和参考价值。更多还原

【Abstract】 Objective To investigate the expression of serum pro-gastrin releasing peptide(ProGRP) and neuron-specific enolase(NSE) in advanced non-small cell lung cancer(NSCLC) and its clinical significance.Methods A total of 75 patients with advanced NSCLC were collected. PorGRP and NSE expression in serum were detected by electrochemiluminescence immunoassay.Results There were no significant differences in serum ProGRP and NSE levels among advanced NSCLC patients with different age, gender, smoking history, Eastern Oncology Cooperative group(ECOG) score and differentiation degree(P>0.05);There was no significant correlation between serum ProGRP and NSE levels and clinical T and N stages of patients with advanced NSCLC(P>0.05);Serum ProGRP and NSE levels were increased as the number of metastatic sites in patients with clinical M stage increased. Serum ProGRP and NSE levels were higher in patients with advanced NSCLC adenocarcinoma than those in patients with squamous cell carcinoma; serum ProGRP and NSE levels were higher in EGFR gene-positive(mutant) patients than those in EGFR gene-negative(wild type) patients, and the differences were statistically significant(P<0.05).Conclusions The expression of serum ProGRP and NSE are related to pathological type, EGFR genotype and number of metastases in clinical TNM stages in patients with advanced NSCLC, it has higher detection significance and reference value for guiding clinical treatment and disease evaluation.更多还原